Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia is an aggressive hematologic cancer marked by uncontrolled proliferation of myeloid precursor cells. Diagnosis relies on genetic and molecular features.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Acute Myeloid Leukemia (AML) in FDA labeling.
Defined at the solid tumor level and applicable to Acute Myeloid Leukemia (AML) and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Acute Myeloid Leukemia (AML). Select a therapy to view the specific approval and eligible tests.
IDH2 (R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W)
IDH1 (R132 mutations (R132C, R132H, R132G, R132S, and R132L))
FLT3 (ITD/TKD) (ITD mutations and TKD mutations D835 and I836)
IDH1 (R132 mutations (R132C, R132H, R132G, R132S, and R132L))
FLT3 (ITD/TKD) (ITD mutations and TKD mutations D835 and I836)
FLT3 (ITD/TKD) (ITD mutations and TKD mutations D835 and I836)